Thermo Fisher Launches Cas-9 Protein to Support Genome Editing
The GMP-manufactured Gibco CTS TrueCut Cas9 Protein provides consistent high-editing efficiency in all tested cell lines and greater than 90% efficiency in human primary T-cells.
Source: Getty Images
By - Thermo Fisher Scientific recently introduced the GMP-manufactured Gibco CTS TrueCut Cas9 Protein to help researchers meet stringent quality requirements when using genome editing tools.
Gibco CTS TrueCut Cas9 Protein provides consistent high-editing efficiency in all tested cell lines and greater than 90% efficiency in human primary T-cells, making it an attractive solution for CAR T-cell therapy research using CRISPR-Cas9 genome editing.
With the addition of a GMP-manufactured Cas9 protein to the Gibco CTS Xenon Electroporation System, Thermo Fisher can now support researchers across the autologous T-cell workflow.
"As genome-editing quality and regulatory requirements continue to evolve, we are focused on providing solutions to meet scientists' needs as they transition from the bench to the clinic," Brandon Pence, vice president and general manager of cell biology at Thermo Fisher Scientific, said in the announcement.
"By adding the Gibco CTS TrueCut Cas9 Protein to our portfolio of genome-editing solutions, we can now support scientists in their journey to develop personalized CAR T-cell therapeutics," Pence continued.
TrueCut Cas9 proteins are manufactured with United States Pharmacopeia standards, including traceability documentation, aseptic manufacturing, and safety testing.
The Gibco CTS TrueCut Cas9 Protein is part of the Thermo Fisher Cell Therapy Systems (CTS) product line, a comprehensive portfolio of GMP-manufactured products supported by traceability documentation.
The product line works synergistically across the entire workflow, from cell isolation/ activation to cell engineering and expansion to address cell therapy developers' manufacturing needs.
Thermo Fisher is the world leader in serving the sciences, with nearly $40 billion in annual revenue.
Last month, the company introduced a new large-volume electroporation system that allows cell therapy developers to move from clinical development to commercial manufacturing quickly.
The Gibco CTS Xenon Electroporation System leverages a closed, flexible design to facilitate gene modifications without traditional viral vectors. The electroporation approach allows a payload into a cell by temporarily boosting cell permeability using an electrical pulse.
And last week, Thermo Fisher launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated, next-generation sequencing (NGS) platform that delivers results in one day.
The platform is designed for clinical laboratories and enables users to perform diagnostic testing and clinical research on a single instrument.
